References
- Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev. 2011 Jan;24:71–109.
- Pew Charitable Trusts. A scientific roadmap for antibiotic discovery. 2016. [cited 2018 Aug 29]. Available from: http://www.pewtrusts.org/~/media/assets/2016/05/ascientificroadmapforantibioticdiscovery.pdf
- Klein EY, Van Boeckel TP, Martinez EM, et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci USA. 2018 Mar;115:E3463–E3470.
- Hughes D, Karlén A. Discovery and preclinical development of new antibiotics. Ups J Med Sci. 2014 May;119:162–169.
- So AD, Ruiz-Esparza Q, Gupta N, et al. 3Rs for innovating novel antibiotics: sharing resources, risks, and rewards. BMJ. 2012 Apr;344:e1782.
- Mossialos E, Morel CM, Edwards S, et al. Policies and incentives for promoting innovation in antibiotic research. Copenhage: European Observatory on Health Systems and Policies; 2010. [cited 2018 Aug 29]. Available from: http://www.euro.who.int/__data/assets/pdf_file/0011/120143/E94241.pdf
- The Review on Antimicrobial Resistance. Securing new drugs for future generations: the pipeline of antibiotics. London; 2015. [cited 2018 Aug 29]. Available from: http://amr-review.org/sites/default/files/SECURING%20NEW%20DRUGS%20FOR%20FUTURE%20GENERATIONS%20FINAL%20WEB_0.pdf
- Chorzelski S, Grosch B, Rentmeister H, et al. Breaking through the wall: enhancing research and development of antibiotics in science and industry. Berlin; 2015. [cited 2018 Aug 29]. Available from: https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/G/G7/Qualita_etswettbewerb_Gesundheitssystem_Whitepaper_2015-10-02_Kurz_engl_….pdf
- Shlaes DM. Research and development of antibiotics: the next battleground. ACS Infect Dis. 2015 May;1:232–233.
- Sharma P, Towse A New drugs to tackle antimicrobial resistance. London: Office of Health Economics; 2011. [cited 2018 Aug 29]. Available from: https://www.ohe.org/publications/new-drugs-tackle-antimicrobial-resistance-analysis-eu-policy-options
- Renwick MJ, Simpkin V, Mossialos E Targeting innovation in antibiotic drug discovery and development: the need for a one health–one Europe–one world framework. Copenhagen: European Observatory on Health Systems and Policies; 2016. [cited 2018 Aug 29]. Available from: http://www.euro.who.int/__data/assets/pdf_file/0003/315309/Targeting-innovation-antibiotic-drug-d-and-d-2016.pdf
- Renwick MJ, Brogan DM, Mossialos E. A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics. J Antibiot. 2016 Feb;69:73–88.
- Simpkin V, Renwick MJ, Kelly R, et al. Incentivizing innovation in antibiotic discovery and development: progress, challenges and next steps. J Antibiot. 2017 Dec;70(12):1087–1096.
- World Health Organization. Antibacterial agents in clinical development. Geneva; 2017. [cited 2018 Aug 29]. Available from: http://www.who.int/medicines/news/2017/IAU_AntibacterialAgentsClinicalDevelopment_webfinal_2017_09_19.pdf?ua=1
- Butler MS, Blaskovich MA, Cooper MA. Antibiotics in the clinical pipeline at the end of 2015. J Antibiot. 2017 Jan;70(1):3–24.
- Czaplewski L, Bax R, Clokie M, et al. Alternatives to antibiotics – a pipeline portfolio review. Lancet Infect Dis. 2016;16:239–251.
- Kelly R, Zoubiane G, Walsh D, et al. Public funding for research on antibacterial resistance in the JPIAMR countries, the European Commission, and related European Union agencies: a systematic observational analysis. Lancet Infect Dis. 2016 Apr;16(4):431–440.
- Brogan DM, Mossialos E. A critical analysis of the review on antimicrobial resistance and the infectious disease finance facility. Global Health. 2016 Mar;12:8.
- DRIVE-AB. Revitalizing the antibiotic pipeline: stimulating innovation while driving sustainable use and global access. 2018. [cited 2018 Aug 29]. Available from: http://drive-ab.eu/wp-content/uploads/2018/01/CHHJ5467-Drive-AB-Main-Report-180319-WEB.pdf
- The Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: final report and recommendations. London; 2016. [cited 2018 Aug 29]. Available from: https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf
- Rex JH, Outterson K. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach. Lancet Infect Dis. 2016 Apr;16:500–505.
- Ferraro JS, Towse A, Ferrandiz J-M Incentives for new drugs to tackle anti-microbial resistance. London: Office of Health Economics; 2017. [cited 2018 Aug 29]. Available from: https://www.ohe.org/publications/incentives-new-drugs-tackle-anti-microbial-resistance.
- Brogan DM, Mossialos E. Systems, not pills: the options market for antibiotics seeks to rejuvenate the antibiotic pipeline. Soc Sci Med. 2016 Feb;151:167–172.
- Brogan DM, Mossialos E. Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model. Global Health. 2013;9:58.
- Paavola A Big pharma backs of superbug: why 5 drugmakers bailed on antibiotic research. Beckers Hospital Review; 2018. [cited 2018 Aug 29]. Available from: https://www.beckershospitalreview.com/pharmacy/big-pharma-backs-off-superbug-why-5-drugmakers-bailed-on-antibiotic-research.html
- G20 leaders’ declaration. Hamburg: Shaping an Interconnected World; 2017. [cited 2018 Aug 29]. Available from: https://www.g20.org/en/g20/timeline